saascode
healthcare & clinical·run 039 · Apr 2026

Annulent

A research-operations workspace for academic medical centers that links grant, ethics-review, protocol, budget, and cohort-feasibility evidence while leaving every approval and clinical decision with its accountable owner.

Genesis score0.00/10
Make Annulent real.0/500
500 more votes and Annulent is authorized for build.
0%500 to authorize
Backing is the vote. When an idea crosses 500, we pull it into the build pipeline and ship it for real — the votes decide what gets built next, not an editor.
The case

Established research-administration suites already combine grants and institutional review workflows, so Annulent's proposed wedge is the governed link to real-world cohort feasibility and clinical data standards. Grant draft, institutional submission, ethics finding, protocol approval, cohort query, feasibility estimate, investigator decision, participant contact, consent, enrollment, budget authorization, and study outcome remain separate.

Who pays — and why

A research administration, clinical research, informatics, grants, or finance leader at an academic medical center or integrated delivery network with multiple siloed systems. Exact role, budget, study volume, replacement appetite, and incumbent contract remain incomplete.

Market signalNo direct price for the proposed research-operations and cohort-feasibility layer was established in the supplied evidence.Observed market reference, not fixed product pricing; no direct price was established
What it unlocks
A shared research record linking sponsor opportunity, grant version, protocol, ethics submission, approvals, amendments, sites, budget, milestones, and accountable owners
Governed cohort-feasibility queries that preserve data source, phenotype definition, inclusion and exclusion logic, date, coverage, uncertainty, reviewer correction, and permitted use
Separate feasibility estimate, investigator decision, recruitment authorization, patient identification, contact permission, consent, enrollment, and clinical outcome
Reconciliation across institutional systems without claiming one new interface replaces official grants, ethics, clinical, finance, or sponsor records
How Genesis scored it
0.00across seven criteria
tension 6temporal 7blindspot 5buyer 5leverage 8convergence 5why-not 4
8
Asymmetric leverage

Common protocol, budget, evidence, and query patterns are reusable, while institution-specific configuration and review remain heavy.

7
Temporal window

Recent open phenotype-extraction activity and an incumbent interoperability gap create a current but non-decisive signal.

4
Why nobody did it

Research interfaces and phenotype tooling exist, but the original record verified neither interface and does not prove a newly broken barrier.

Why it scored well

Large incumbents validate research administration, confirmed institutional interfaces enable bounded integration, and the cohort-feasibility connection offers a concrete differentiation hypothesis.

What's holding it back

The stored score is zero. An established fused suite and a second integrated competitor weaken whitespace, the buyer is underspecified, both original interfaces were unverified, and institutional configuration, privacy, ethics, data quality, validation, change management, and replacement risk are substantial.

Signals detected3 sources crossed
SignalCayuse product review

SignalResearch Insight product review

SignalNIH eRA and REDCap documentation review

Direction briefannulent.md
annulent.md
Want this pointed at your vertical?Point Genesis at your own market and constraints — it invents adjacent, fork-ready ideas, private to you before they hit the public feed.

Discussion

?

No comments yet — be the first to weigh in.